Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Trump Says Anthropic No Longer Seen as National Security Threat 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
 Today (Tuesday, February 2) to Discuss Expansion of Strategic Collaboration Agreement with GlaxoSmithKline (GSK) - EconoTimes)
PHILADELPHIA and OXFORD, United Kingdom, Feb. 02, 2016 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, will host a live teleconference and webcast at 10:00 a.m. Eastern Time (3:00 p.m. GMT) today (Tuesday February 2, 2016) to discuss the expansion of their strategic collaboration with GSK and the acceleration of the NY-ESO program.
The live webcast of the conference call will be made available via Adaptimmune’s corporate website at www.adaptimmune.com on the events page. An archive will be available after the call at the same address.
To participate in the live conference call, if preferred, please dial (877) 280-2296 (U.S.) or +44 (0)20 7136 2056 or 0800 279 4992 (United Kingdom). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (5656147).
About Adaptimmune
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. Established in 2008, the company aims to utilize the body’s own machinery - the T-cell - to target and destroy cancer cells by using engineered, increased affinity TCRs as a means of strengthening natural patient T-cell responses. Adaptimmune’s lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. In addition, Adaptimmune has a number of proprietary programs. The company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing 12 through unpartnered research programs. Adaptimmune has over 200 employees and is located in Oxfordshire, U.K. and Philadelphia, USA. For more information: http://www.adaptimmune.com.
Adaptimmune Contacts Will Roberts Vice President, Investor Relations T: (215) 825-9306 E: [email protected] Margaret Henry Head of PR T: +44 (0)1235 430036 Mob: +44 (0)7710 304249 E: [email protected]
